Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Pharvaris N.V.

35 indications, side-by-side phase, drug & LoA

$32.2

+0.69 (+2.19%)

C 49Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.94 B
EPS
-3.18
P/E Ratio
-
Value Trade
20.96 M
-2.18 %
Week
0.37 %
1 Month
5.7 %
3 Month
22.44 %
6 Month
33.64 %
5 Year
18.72 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
396.73 K
52 Week Range
15.46 - 33.33
% held by Insiders
57.6 %
% held by Institutions
40.34 %
Enterprise Value
1.66 B
Total Shares
65.41 M
Short %
2.41 %
Float Shares
27.71 M
Company Description
Employees:129
https://www.pharvaris.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
Deucrictibant immediate-release capsule Hereditary angioedema attacks
Phase 3
—
Small Molecules
Rare Diseases
Deucrictibant immediate-release capsule Hereditary angioedema attacks
Phase 3
—
Small Molecules
Rare Diseases
Deucrictibant immediate-release capsule Hereditary angioedema attacks
Phase 3
—
Small Molecules
Rare Diseases
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C49
Pipeline Score
$584M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 70%
Micro Cap
(rank 272 of 905)
Percentile Rank
Pharvaris N.V. carries a moderate pipeline score (49/100), with $1.6B risk-adjusted pipeline value, led by Deucrictibant in Hereditary Angioedema (HAE) (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Deucrictibant
Small molecule		Hereditary Angioedema (HAE)Phase 3NCT0666975486% $1.3B ACTIVE NOT_RECRUITING 251 AVERAGE B (69) Aug 1, 2026LOW_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Deucrictibant
Hereditary Angioedema,Acquired Angioedema due to C1 inhibitor deficiency
Phase 3
2025-06-27
Deucrictibant
Hereditary Angioedema,Acquired Angioedema due to C1 inhibitor deficiency
Phase 3
2025-06-27
Deucrictibant
Hereditary Angioedema,Acquired Angioedema due to C1 inhibitor deficiency
Phase 3
2025-06-27
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PHVS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PHVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PHVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PHVS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
PHVS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
PHVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Pharvaris N.V. (PHVS) News & Alerts
-
Friday, June 12, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How PHVS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Rare Immunological Disorders #1 of 10 PHASE 3 Deucrictibant
AMGN ZBIO IONS
—0.97 LEADER
Hereditary Angioedema #5 of 7 PHASE 2 deucrictibant
NTLA BCRX IONS
$6.83B 0.98 CONTENDER